SCHEMBL6004995

SCHEMBL6004995

O=C(O)C(Cc1ccc(Cl)c(Cl)c1)c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
PTPN1 P18031 1/20 0.39
MAPK1 P28482 2/20 0.39
FPR2 P25090 1/20 0.39
CHEK1 O14757 1/20 0.39
ROCK2 O75116 1/20 0.39
RPS6KA5 O75582 1/20 0.39
MAP4K4 O95819 1/20 0.39
CHEK2 O96017 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854480 0.87 EPHX1 (0.46) PNMTCYP3A4CYP2D6CYP1A2CYP2C9
SCHEMBL6005718 0.86 FPR2 (0.51) PNMTCYP2C19PPARGPPARAPTPN1
SCHEMBL6003758 0.86 FPR2 (0.51) PNMTCYP2C19PPARGPPARAPTPN1
SCHEMBL6005310 0.86 FPR2 (0.51) PNMTCYP2C19PPARGPPARAPTPN1
SCHEMBL9109006 0.85 CYP2C9 (0.49) PNMTCYP2D6CYP2C9CYP2C19SLC6A2
SCHEMBL6006575 0.82 KMT2A (0.49) PNMTPPARGPPARAPTPN1FPR2
SCHEMBL6005803 0.82 PPARA (0.50) PNMTCYP2D6CYP1A2CYP2C9CYP2C19
SCHEMBL6005083 0.77 PPARG (0.43) PNMTCYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL6005468 0.77 PPARG (0.43) PNMTCYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL17663905 0.76 S1PR3 (0.55) PTPN1MAPK1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP PNMT 479/4885CYP3A4 212/4885CYP2D6 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.